PRESS-RELEASE ·Filed May 11, 2026

CHRS

Coherus Oncology, Inc.
MIXED
Impact 6/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight ◆ Mixed

The EPS beat is overshadowed by a clear revenue miss and heavy dilution from the Q1 offering. Watch for mid-2026 pipeline data readouts (casdozokitug, tagmokitug) as key catalysts; the $167M cash position provides runway but operating burn remains high at ~$58M/quarter.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CHRS ▼ -26.02% at T+60d
NEUTRAL call ✗ call lost -26.02% · α vs SPY -30.41% · entry $1.71 → $1.27
Entry anchored
May 11, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -0.54%
$1.71
settled 5mo ago
T+5d
-12.87%
call -12.87% · α -12.94%
$1.49
settled 5mo ago
T+20d
-20.47%
call -20.47% · α -18.74%
$1.36
settled 4mo ago
T+60d
-26.02%
call -26.02% · α -30.41%
$1.27
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14.3M estimate by 14.0%. LOQTORZI revenue grew 61% YoY to $11.8M, but total revenue was dragged lower than expected, and the company completed a dilutive $53.6M equity offering during the quarter.

Key Financial Metrics

EPS
$-0.27
est $-0.29 · +6.9%
Revenue
$12.3M
est $14.3M · -13.9% · +62.0% YoY
Rating
miss
Gross Margin
69%

Key Facts

  • GAAP EPS from continuing operations: -$0.27 vs consensus -$0.29 (beat by 6.9%)
  • Revenue: $12.3M vs consensus $14.3M (miss by 14.0%)
  • LOQTORZI net product revenue: $11.8M, up 61% YoY from $7.3M
  • Net loss from continuing operations improved to -$36.9M from -$47.4M YoY
  • Cash, equivalents and marketable securities: $167.0M at quarter-end
  • Completed public offering of 32.89M shares for net proceeds of $53.6M in Q1 2026
  • Operating cash flow: -$57.9M in Q1 2026 vs -$25.8M in Q1 2025
  • Pipeline catalysts: casdozokitug Phase 2 1L HCC data expected mid-2026; tagmokitug multiple readouts in 2026

Financial Impact

Revenue miss of $2.0M (14%) vs consensus; EPS beat of $0.02 (6.9%); $53.6M dilutive equity offering increased share count by ~31%

revenueepsdilutioncash

Risk Factors

  • Revenue miss of 14% vs consensus signals weaker-than-expected LOQTORZI adoption
  • Dilution of ~31% from Q1 equity offering pressures per-share metrics
  • Operating cash burn of -$57.9M in Q1 2026, up from -$25.8M YoY
  • Heavy reliance on pipeline data readouts for valuation inflection

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292299
11 reports for CHRS
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+5▲ +16.97%Feb 28, 2026
Filters
Rows
Reports for CHRS — sortable, filterable
TypeNow
Aug 17, 2026
6w ago
Press Release
NEUTRAL ★ 4/10
$1.34 $1.29▼ −4.10%▼ −3.11%$1.16 (−13.43%)
Jul 22, 2026
10w ago
Press Release
NEUTRAL ★ 1/10
$1.43 $1.33▼ −6.99%▼ −9.89%$1.16 (−18.88%)
Jun 15, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$1.38 $1.45▲ +5.07%▲ +4.87%$1.16 (−15.94%)
Jun 12, 2026
16w ago
Institutional Cluster
BEARISH ★ 4/10
$1.40 $1.54▼ −10.00%▼ −8.22%$1.16 (+17.14%)
May 28, 2026
18w ago
DEFA14A
NEUTRAL ★ 4/10
$1.65 $1.50▼ −9.09%▼ −5.95%$1.16 (−29.70%)
May 11, 2026
20w ago
Press Release
MIXED ★ 6/10
$1.71 $1.36▼ −20.47%▼ −18.74%$1.16 (−32.16%)
May 5, 2026
21w ago
DEFA14A
NEUTRAL ★ 2/10
$1.75 $1.47▼ −16.00%▼ −18.78%$1.16 (−33.71%)
May 4, 2026
21w ago
Press Release
NEUTRAL ★ 1/10
$1.73 $1.57▼ −9.25%▼ −14.89%$1.16 (−32.95%)
Mar 9, 2026
29w ago
Press Release
BULLISH ★ 8/10
$1.95 $1.70▼ −12.82%▼ −12.67%$1.16 (−40.51%)
Mar 2, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$1.65 $1.60▼ −3.03%▲ +4.91%$1.16 (−29.70%)
Showing 10 of 11

US Market Status

Market Closed — Opens Mon (38h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 11, 2026